Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly’s profit doubled in the fourth ... Mounjaro and Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring in popularity globally ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...